Tag: life science
NOME Annual Meeting in Copenhagen on November 23rd 2021
Sartar participated the NOME Annual Meeting on 23rd Nov 2021 in Copenhagen, meeting mentors and other life science and medtech startups. NOME is an elite Nordic Mentoring Program that matches selected Nordic startups with highly skilled professionals to help them reach their goals and technology milestones. Sartar was selected to the program last June and has […]
Sartar Therapeutics was selected to NOME mentoring program
Sartar Therapeutics was selected to NOME (Nordic Mentor Network for Entrepreneurship), an elite Nordic Mentoring program that connects most promising life science startups with highly skilled relevant professionals to help them reach their goals and technology milestones. We had our first mentoring session with lots of valuable insights and are eager to continue the journey […]
Mikael Maksimow joins Sartar as a COO. Welcome!
We are happy to announce Mikael Maksimow has joined our team as a COO. Welcome Mikael! Mikael has broad experience in drug development from innovations to international clinical trials. His experience in advancing start-up companies will be a great addition to our small but efficient team.
Sartar was selected to participate as one of the Rising Stars at Nordic Life Science Invest
We are happy to be selected as one of the rising star companies at Nordic Life Science Invest Days. Link to NLS Days website
Sartar has been selected as one of only six finalists at the NOME Startup Competition
Sartar was selected among close to 100 other companies who also applied to the competition. “I think the six selected cases are very interesting and definitely represent those who have the highest potential and the best traction”, says Peter Birk, Accelerace. Read original article
Sartar Therapeutics investment round was a success
Sartar’s investment round closed ahead of time on Monday (19.10.2020). We achieved incredible outcome of 2 300 000 euros just in six days. Sartar wishes to thank all investors for taking part in the round. We would also like to thank Springvest, for helping us to achieve this goal. Thank you!
Sartar was chosen among the top 30 innovative life science companies in RESI Innovation Challenge
We are honored to be selected as one of the most innovative companies in RESI Europe 2020 Innovation Challenge in the therapeutics category. Link to original news
Sartar was granted a Japan patent
Sartar was awarded a patent in Japan for the use of anagrelide in cancer therapy.
Pekka Simula joins Sartar’s board of directors
Sartar strengthens the board of directors. CEO of Herantis Pharma, Pekka Simula, has been appointed as a new member to the Sartar Therapeutics board of directors.
Sartar was awarded a U.S. patent
Sartar was awarded a U.S. patent for use of anagrelide in cancer therapy.